BENITIONSClinical Trial Intelligence

Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Treatment of UC

Не применимо Завершено NCT06591013

ЗаболеваниеInflammatory Bowel Diseases
ФазаНе применимо
СпонсорFirst Affiliated Hospital of Kunming Medical University
СтатусЗавершено
Участники102 участн.
ВмешательствоFecal microbiota transplantation
Дата начала14.10.2024
Дата завершения20.10.2025
Публикация результатов30.06.2026

Кратко

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), affects over 2 million people worldwide . Although biological therapies have significantly improved the treatment outcomes for UC, nearly two-thirds of patients experience diminishing drug responses over time, making it crucial to explore novel therapeutic approaches targeting the underlying pathophysiology of UC. UC is associated with alterations in gut microbiota, reduced microbial diversity, and changes in the relative abundance of dominant bacterial populations. Specifically, UC patients exhibit a marked decrease in gut microbiota diversity at the species level, with a reduction in Firmicutes (e.g., Clostridium butyricum) and an increase in Actinobacteria, Proteobacteria (e.g., Escherichia coli), Enterobacteriaceae, Streptococcus, and Bacteroides . Given the association between gut microbiota alterations and IBD activity, several studies have proposed microbiota-based therapies, particularly fecal microbiota transplantation (FMT), as a treatment for UC.

a Composite of Steroid-free Clinical Remission Together With Endoscopic Remission or Response

12 weeks after fecal microbiota transplantation · Participants

the Bai Nationality-UC24 Participants
the Han Nationality-UC16 Participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.